Showing 2871-2880 of 7618 results for "".
- FDA Accepts Arcutis’ sNDA for Roflumilast Cream 0.15% for Treatment of AD in Adults and Children Down to Age 6https://practicaldermatology.com/news/fda-accepts-arcutis-snda-for-roflumilast-cream-015-for-treatment-of-ad-in-adults-and-children-down-to-age-6/2462159/The U.S. Food and Drug Administration (FDA) has accepted Arcutis’ supplemental new drug application (sNDA) for roflumilast cream 0.15% for the treatment of atopic dermatitis (AD) in adults and children down to age 6. Roflumilast cream is a once-daily, steroid
- Taking a Joint Approach to Treating PsA and PsO: One Rheumatologist’s Advice on Working With Dermatologistshttps://practicaldermatology.com/news/taking-a-joint-approach-to-treating-psa-and-pso-one-rheumatologists-advice-on-working-with-dermatologists/2462158/Psoriasis (PsO) and psoriatic arthritis (PsA) often travel together, which is why dermatologists and rheumatologists need to collaborate and ensure that patients receive the best and most appropriate care for their skin and joints. Around one in three people with PsO also have PsA, acco
- Regenerative Medicine in Action: Reprogramming Tissue Mechanically to Heal Wounds, Rejuvenate Skinhttps://practicaldermatology.com/news/regenerative-medicine-in-action-reprogramming-tissue-mechanically-to-heal-wounds-rejuvenate-skin/2462156/Researchers have taken connective tissue cells that have been mechanically reprogrammed to resemble stem cells and transplanted them into damaged skin. In their laboratory experiment, they were able to show that the skin tissue model can actually be rejuvenated and that injur
- AD Pipeline Watch: Escient Pharmaceuticals Initiates Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonisthttps://practicaldermatology.com/news/ad-pipeline-watch-escient-pharmaceuticals-initiates-proof-of-concept-study-of-ep262-a-first-in-class-oral-mrgprx2-antagonist/2462155/The first subject has been dosed in EASE, a Phase 2a clinical proof-of-concept study of Escient Pharmaceuticals’ EP262 in atopic dermatitis (AD). By blocking activation of MRGPRX2 and degranulation of mast cells, EP262 has the potential to effectively treat multiple mast cell medi
- FDA Grants Priority Review for Abeona's Pz-cel BLAhttps://practicaldermatology.com/news/fda-grants-priority-review-for-abeonas-pz-cel-bla/2462154/The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the Biologics License Application (BLA) of Abeona Therapeutics Inc.’s pz-cel (prademagene zamikeracel), an investigational autologous, COL7A1 gene-corrected epidermal sheets for the treatment of patient
- AD Pipeline Watch: Oral Zelnecirnon Shows Early Promise in ADhttps://practicaldermatology.com/news/ad-pipeline-watch-oral-zelnecirnon-shows-early-promise-in-ad/2462153/Zelnecirnon performed well in a Phase 1a/1b clinical trial of atopic dermatitis (AD), RAPT Therapeutics reports. Zelnecirnon is a small molecule oral therapy designed to selectively inhibit the migration of Th2 cells into inflamed tissues by blocking CCR4, a receptor highly express
- Can a New Bacteriocin Thwart Antibiotic Resistance?https://practicaldermatology.com/news/can-a-new-bacteriocin-thwart-antibiotic-resistance/2462150/A new bacteriocin in a very common skin bacterium may inhibit the growth of antibiotic-resistant bacteria, new research suggests. The research group for child and youth health at UiT The Arctic University of Norway has studied bacter
- Melanoma and Lung Cancer Drug May Also Treat Cutaneous Squamous Cell Carcinomahttps://practicaldermatology.com/news/melanoma-and-lung-cancer-drug-may-also-treat-cutaneous-squamous-cell-carcinoma/2462149/Plixorafenib, a new drug developed for treating melanoma and lung cancer, may also stop the progression of cutaneous squamous cell carcinoma, new research suggests. Researchers out of the University of Turku, Finland, discovered that plixorafenib (also called PLX8394) simultaneously inh
- Demystifying Itch: Does S. aureus Kickstart a Molecular Chain Reaction That Culminates in the Urge to Scratch?https://practicaldermatology.com/news/demystifying-itch-does-s-aureus-kickstart-a-molecular-chain-reaction-that-culminates-in-the-urge-to-scratch/2462148/Staphylococcus aureus may cause itch by acting directly on nerve cells. The findings, based on research in mice and in human cells, are reported Nov. 22 in Cell. In eczema and atopic dermatitis, the equilibrium of microorganisms that keep skin he
- Take That, Melanoma! ATM Kinase Inhibitors May Stop Metastasishttps://practicaldermatology.com/news/take-that-melanona-atm-kinase-inhibitors-may-stop-metastasis/2462146/Ataxia telangiectasia mutated (ATM) kinase inhibition may target the metastatic capacity of melanoma cells, according to a research team led by Wolfgang Weninger and Shweta Tikoo from MedUni Vienna's Department of Dermatology. The results of the study, which appe